my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
17-08-2012: Algeta ASA announced it has initiated a new research and development program aimed at investigating the effect of a novel Targeted Thorium Conjugate (TTC) on hematological cancers.
The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to the alpha-particle emitter thorium-227 (Th-227).
This new program represents Algeta’s fourth TTC program and as part of the project the Company has entered into a fee-for-service agreement with Cobra Biologics, which will manufacture the antibody in its GMP-approved facility in Södertälje, Sweden. Algeta has already demonstrated it can chelate Th-227 to this antibody in exploratory studies.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Algeta US Celebrates Official Opening of Operational Center in Cambridge, MA
Algeta ASA celebrated the official opening of the offices and facilities of Algeta US in Cambridge, Massachusetts.In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of Alpharadin. Under the terms of the agreement, Bayer will develop, apply for ... more
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
Cobra Biologics Ltd and Algeta ASA announced a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program. The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target ... more
Algeta is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. The Company is targeting metastatic and disseminated tumor types for which there is substantial unmet medical need. Its first product candi ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
